ClinicalTrials.gg
CompletedNCT00779636Updated Aug 15, 2024

Effectiveness and Safety of Desloratadine in Patients With Allergic Airway Disease During the Pollen Season (Study P03284)

A Phase 4 interventional study of Desloratadine and Placebo in Allergic Airway Disease, sponsored by Organon and Co. Completed. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-08-15.

Sponsored by Organon and Co · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 5 years 3 months after the study started (first participant enrolled Jul 2003, registered Oct 2008).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
506
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This was a placebo controlled study designed to evaluate the effectiveness of desloratadine in relieving symptoms of allergic airway disease during the pollen season. Patients received desloratadine 10 mg or placebo once daily for 28 days, and had their allergy symptoms and side effects to medication measured on Day 1, Day 15, and Day 29 (one day after stopping study drug).

02

Conditions studied

  • Allergic Airway Disease
03

In context

Lead sponsor

Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.

Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 - 65 years old
  • at least a two-year history of seasonal allergic rhinitis and the presence of chest symptoms (cough, wheezing, difficulty breathing) associated with the allergy season
  • was greater than or equal to 70% of predicted
  • skin test positive (skin prick test)
  • Total Nasal Symptom Severity Score of >= 6 at the Screening Visit.
  • Total Chest Symptom Severity Score of >= 3 at the Screening Visit.
  • Total Frequency of Chest Symptoms and/or Total Frequency of Bronchodilator Use of at least 2 at the Screening Visit
  • Total Nasal Symptom Severity Score was >= 6 on 7 of the 15 run-in diary timepoints.
  • Total Chest Symptom Severity Score was >= 3 on 7 of the 15 run-in diary timepoints
  • Free of any disease that would interfere with the study evaluations.

Exclusion criteria

Exclusion Criteria:

Subjects who:

  • demonstrated a change in of >= 20% between Visit 2 and Visit 3.
  • used >12 puffs of Proventil® HFA (or other beta-2-agonist) on any 2 consecutive days or treatment with nebulized beta-2 agonists during the screening period - between Visit 2 and Visit 3.
  • required chronic use of inhaled or systemic .
  • required regular treatment with nebulized beta2-agonists.
  • required short acting beta-2 agonists use before every exercise session or exposure to an animal.
  • have current or history of frequent (2 or more episodes per year for the past 2 years), sinusitis or chronic purulent postnasal drip.
  • have rhinitis medicamentosa or (COPD).
  • had an upper or lower respiratory tract or sinus infection that required antibiotic therapy with the last dose 14 days prior to Screening, or who have had a upper or lower viral respiratory infection within 7 days prior to Screening.
  • had nasal structural abnormalities, including large nasal polyps and marked septal deviation that significantly interfered with nasal air flow.
  • in the opinion of the Investigator, were dependent upon nasal, oral or ocular decongestants, nasal topical antihistamines, or nasal steroids.
  • are on immunotherapy (desensitization therapy), unless on a regular maintenance schedule prior to the Screening visit and staying on this schedule for the remainder of the study. Subjects could not receive desensitization treatment within 24 hours prior to a study visit.
  • smoke, or ex-smokers who had smoked within the previous six months.
  • had current evidence of clinically significant hematopoietic, cardiovascular, hepatic, immunologic, renal, neurologic, psychiatric, disease, or other disease that precludes the subject's participation in the study or with the subject's ability to complete the diary cards.
  • were morbidly obese ( >= 35).
  • were night-shift workers and those who did not have a standard asleep at night / awake during the day cycle.
  • had any history of life threatening asthma attacks or subjects who had been treated in the emergency room or been admitted to the hospital for asthma control within the previous 3 months or more than once in the previous 6 months.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
506 participants (actual)

Study arms

  • Experimental
    Desloratadine 10 mg

    Drug: Desloratadine

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Desloratadine 10 mg daily x 28 days

    Also known as: Clarinex, SCH 034117

  • DrugPlacebo

    Placebo daily x 28 days

06

What researchers measure

Primary outcomes

  1. Change in FEV1 averaged over weeks 1 to 4.

    Time frame: Over weeks 1 to 4

Secondary outcomes

  1. Change from Baseline in chest symptoms, nasal symptoms, and eye symptom scores

    Time frame: Day 15 and Day 29

  2. Interference with sleep and daily activities

    Time frame: Day 15 and Day 29

  3. Number of nocturnal awakenings due to chest symptoms

    Time frame: Day 15 and Day 29

  4. Overall Therapeutic Response to therapy of allergic airway disease symptoms (investigator and joint evaluation)

    Time frame: Day 15 and Day 29

  5. Change from Baseline in chest symptoms, nasal symptoms, and eye symptom scores

    Time frame: ALL TREATMENT VISITS (Day 1, Day 15, and Day 29)

  6. Change in FEV1, FVC, FEF(25%-75%), PEFR

    Time frame: ALL TREATMENT VISITS (Day 1, Day 15, and Day 29)

  7. Use of Proventil® HFA rescue medication

    Time frame: ALL TREATMENT VISITS (Day 1, Day 15, and Day 29)

  8. Interference with sleep and daily activities

    Time frame: ALL TREATMENT VISITS (Day 1, Day 15, and Day 29)

  9. Number of nocturnal awakenings due to chest symptoms

    Time frame: ALL TREATMENT VISITS (Day 1, Day 15, and Day 29)

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2003 to primary completion in Nov 2004, 16 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2008
First posted
Oct 24, 2008
StartActual
Jul 1, 2003
Primary completionActual
Nov 1, 2004
CompletionActual
Nov 1, 2004
Last update
Aug 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00779636
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
Oct 24, 2008
Start date
Jul 1, 2003
Primary completion
Nov 1, 2004
Completion
Nov 1, 2004
Last update
Aug 15, 2024

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Desloratadine

Start the discussion